BiomOrgan proudly announces that our founder, Prof. Zhou Jie, has co-led the development of the world’s first nasal organoid-based neutralization assay platform. This breakthrough enables precise evaluation of neutralizing antibodies and vaccine candidates using human nasal epithelial organoids offering physiologically relevant modeling of respiratory viral infections.

The platform supports high-throughput screening and translational research, accelerating the development of next-generation immunotherapies. Prof. Zhou’s leadership continues to drive innovation in respiratory organoid science and reinforce BiomOrgan’s global impact.

➡️ Read Full Press Release

Partnership Inquiries: bd@biomorgan.hk